Extrapyramidal side-effects and dopamine D(2/3) receptor binding in substantia nigra. 2010

Heli Tuppurainen, and Jyrki T Kuikka, and Heimo Viinamäki, and Minna Husso, and Jari Tiihonen
Department of Forensic Psychiatry, University of Kuopio, Niuvanniemi Hospital, FI-70240 Kuopio, Finland. heli.tuppurainen@niuva.fi

BACKGROUND The exact mechanisms for antipsychotic-induced extrapyramidal side-effects have remained obscure despite intensive research. Previous studies have highlighted a central role for nigral dopamine D(2) receptors in the control of motor functions. OBJECTIVE The aim of the present study was to examine relationships between dopamine D(2) receptor binding in both substantia nigra and temporal cortex with extrapyramidal symptoms among antipsychotic-treated patients with schizophrenia. METHODS Single-photon emission-computed tomography (SPECT) ligand [(123)I]epidepride was used to determine dopamine D(2/3) apparent binding potential in 13 antipsychotic-treated (seven with clozapine, four with olanzapine and two with haloperidol) patients with schizophrenia. Extrapyramidal symptoms were assessed with the Simpson and Angus Scale (SAS). RESULTS A statistically significant correlation was observed between dopamine D(2/3) receptor apparent binding potential in the substantia nigra and extrapyramidal side-effects (r = -0.62, P = 0.024). No correlations were detected in the temporal cortex between dopamine D(2/3) receptor binding and extrapyramidal side-effects. CONCLUSIONS These findings support the role of dopamine D(2) autoreceptors in substantia nigra regarding drug-induced movement disorders.

UI MeSH Term Description Entries
D008297 Male Males
D001931 Brain Mapping Imaging techniques used to colocalize sites of brain functions or physiological activity with brain structures. Brain Electrical Activity Mapping,Functional Cerebral Localization,Topographic Brain Mapping,Brain Mapping, Topographic,Functional Cerebral Localizations,Mapping, Brain,Mapping, Topographic Brain
D003024 Clozapine A tricylic dibenzodiazepine, classified as an atypical antipsychotic agent. It binds several types of central nervous system receptors, and displays a unique pharmacological profile. Clozapine is a serotonin antagonist, with strong binding to 5-HT 2A/2C receptor subtype. It also displays strong affinity to several dopaminergic receptors, but shows only weak antagonism at the dopamine D2 receptor, a receptor commonly thought to modulate neuroleptic activity. Agranulocytosis is a major adverse effect associated with administration of this agent. Clozaril,Leponex
D005260 Female Females
D006220 Haloperidol A phenyl-piperidinyl-butyrophenone that is used primarily to treat SCHIZOPHRENIA and other PSYCHOSES. It is also used in schizoaffective disorder, DELUSIONAL DISORDERS, ballism, and TOURETTE SYNDROME (a drug of choice) and occasionally as adjunctive therapy in INTELLECTUAL DISABILITY and the chorea of HUNTINGTON DISEASE. It is a potent antiemetic and is used in the treatment of intractable HICCUPS. (From AMA Drug Evaluations Annual, 1994, p279) Haldol
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000077152 Olanzapine A benzodiazepine derivative that binds SEROTONIN RECEPTORS; MUSCARINIC RECEPTORS; HISTAMINE H1 RECEPTORS; ADRENERGIC ALPHA-1 RECEPTORS; and DOPAMINE RECEPTORS. It is an antipsychotic agent used in the treatment of SCHIZOPHRENIA; BIPOLAR DISORDER; and MAJOR DEPRESSIVE DISORDER; it may also reduce nausea and vomiting in patients undergoing chemotherapy. 2-Methyl-4-(4-methyl-1-piperazinyl)-10H-thieno(2,3-b)(1,5)benzodiazepine,LY 170053,LY-170052,Olanzapine Pamoate,Zolafren,Zyprexa,LY 170052,LY170052
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D001569 Benzodiazepines A group of two-ring heterocyclic compounds consisting of a benzene ring fused to a diazepine ring. Benzodiazepine,Benzodiazepine Compounds
D012559 Schizophrenia A severe emotional disorder of psychotic depth characteristically marked by a retreat from reality with delusion formation, HALLUCINATIONS, emotional disharmony, and regressive behavior. Dementia Praecox,Schizophrenic Disorders,Disorder, Schizophrenic,Disorders, Schizophrenic,Schizophrenias,Schizophrenic Disorder

Related Publications

Heli Tuppurainen, and Jyrki T Kuikka, and Heimo Viinamäki, and Minna Husso, and Jari Tiihonen
October 1985, Life sciences,
Heli Tuppurainen, and Jyrki T Kuikka, and Heimo Viinamäki, and Minna Husso, and Jari Tiihonen
October 2002, Synapse (New York, N.Y.),
Heli Tuppurainen, and Jyrki T Kuikka, and Heimo Viinamäki, and Minna Husso, and Jari Tiihonen
January 1990, Neurochemistry international,
Heli Tuppurainen, and Jyrki T Kuikka, and Heimo Viinamäki, and Minna Husso, and Jari Tiihonen
August 1989, European journal of pharmacology,
Heli Tuppurainen, and Jyrki T Kuikka, and Heimo Viinamäki, and Minna Husso, and Jari Tiihonen
January 1991, Fundamental & clinical pharmacology,
Heli Tuppurainen, and Jyrki T Kuikka, and Heimo Viinamäki, and Minna Husso, and Jari Tiihonen
March 1976, Nature,
Heli Tuppurainen, and Jyrki T Kuikka, and Heimo Viinamäki, and Minna Husso, and Jari Tiihonen
February 2004, Journal of clinical psychopharmacology,
Heli Tuppurainen, and Jyrki T Kuikka, and Heimo Viinamäki, and Minna Husso, and Jari Tiihonen
September 2009, Addiction biology,
Heli Tuppurainen, and Jyrki T Kuikka, and Heimo Viinamäki, and Minna Husso, and Jari Tiihonen
May 1989, Journal of neurology, neurosurgery, and psychiatry,
Heli Tuppurainen, and Jyrki T Kuikka, and Heimo Viinamäki, and Minna Husso, and Jari Tiihonen
March 2003, Synapse (New York, N.Y.),
Copied contents to your clipboard!